SynaptiX End User License Agreement (EULA)

Effective Date: June 30, 2026

1. Parties to this Agreement

This End User License Agreement (the "Agreement") is a binding legal contract between you, the person installing and using the software (the "User", "you", or "your"), and Paris Valentino Iason Kollias, a sole proprietor based in Ontario, Canada, who operates SynaptiX (the "Operator", "we", "us", or "our").

By installing, activating, or using SynaptiX, you agree to be bound by this Agreement.

If you do not agree, do not purchase, install, activate, or use SynaptiX. The checkout flow at synaptix.bio presents this Agreement (along with the Privacy Policy and Terms of Service) for review and acceptance before payment is collected, so that you have an explicit opportunity to decline before purchase.

If you purchased without being given an opportunity to review this Agreement (for example, due to a checkout-flow error), contact us at hi@synaptix.bio. Separately, Section 9 of this Agreement describes the refund policy for compatibility issues and records the status of the future SynaptiX+ add-on. Nothing in this Agreement limits any non-waivable cancellation, refund, or other rights you may have under applicable consumer protection legislation.

2. Definitions

In this Agreement:

"Software" means the SynaptiX desktop application, including all updates, bug fixes, and accompanying documentation provided by the Operator.
"License" means the right granted to you under this Agreement to use the Software.
"License Key" means the alphanumeric activation credential delivered to you by email after purchase.
"Device" means a single physical computer (or virtual machine) running an operating system supported by the Software.
"Tier" means the level of the License you have purchased — either the "Individual" tier or the "Family" tier.
"SynaptiX+" means a possible future, optional add-on to an Individual or Family License. It is not a standalone Tier and is not currently offered for purchase. "Dr. Prime+" is a permanently deprecated former name for that concept.

3. License grant

Subject to your compliance with this Agreement and your payment of the applicable fee, the Operator grants you a non-exclusive, non-transferable, revocable, worldwide license to install, activate, and use the Software on the number of Devices permitted by your Tier:

Individual Tier: up to 3 (three) Devices simultaneously.
Family Tier: up to 10 (ten) Devices simultaneously.

This License is granted to you, personally, for personal use.

You must be at least 18 years old, or the age of majority in your jurisdiction if higher, to purchase this License.

The base profile capacities are:

Individual Tier: 1 (one) local profile.
Family Tier: 4 (four) total local profiles, including the purchaser's profile.

SynaptiX+ does not currently add profiles or features because it is not currently sold or active. If SynaptiX+ is launched later, the intended profile capacities are two profiles on an Individual License and six total profiles on a Family License. Those future capacities create no present entitlement and may be activated only through terms shown and accepted at that future launch.

You may use an available profile seat to analyze your own raw DNA data. You may analyze another adult's DNA only after that adult gives their own explicit informed consent. You may create a profile for a person aged 13–17 only when a parent or legal guardian with authority to act for that minor gives consent and the minor separately assents. SynaptiX does not accept profiles for anyone under 13.

Local analysis consent and cloud AI are separate decisions. Cloud AI is optional and controlled per profile. An adult profile owner decides for themselves. Cloud AI begins off for a profile aged 13–17 and can be enabled only after both the guardian and the minor separately agree; either may refuse or withdraw. When that person turns 18, the earlier guardian consent and minor assent stop authorizing new analysis and cloud AI. Existing reports remain readable, but the now-adult profile owner must review the current terms and decide independently before new analysis or cloud AI resumes.

4. Restrictions

You may NOT:

(a) Use the Software for the diagnosis, treatment, cure, or prevention of any disease or medical condition. SynaptiX is an informational tool and is not approved, cleared, or certified by any regulatory authority (including the United States Food and Drug Administration, Health Canada, or the European Medicines Agency) for medical use.

(b) Resell, redistribute, rent, lease, sublicense, or otherwise transfer the Software or any License Key to any other person or entity.

(c) Reverse-engineer, decompile, disassemble, or attempt to derive the source code of the Software, except to the extent that such activities are expressly permitted by applicable law notwithstanding this restriction.

(d) Modify the Software, create derivative works of it, or remove any proprietary notices or labels embedded in it.

(e) Circumvent or attempt to circumvent the License Key activation system, the Device activation limits, or any other technical protection measures.

(f) Use the Software to analyze another person's DNA without the consent required by Section 3. For an adult, that means the adult's own informed consent. For a person aged 13–17, that means consent from a parent or legal guardian who has authority to act for the minor and the minor's separate assent. You may not create or analyze a profile for anyone under 13. You must not falsely claim guardian authority, complete the minor's assent on their behalf, or continue relying on guardian/minor consent after the profile owner reaches 18.

(g) Use the Software in any manner that violates applicable laws or regulations, including (without limitation) the Personal Information Protection and Electronic Documents Act of Canada ("PIPEDA"), the General Data Protection Regulation of the European Union ("GDPR"), or the Genetic Information Nondiscrimination Act of the United States ("GINA").

5. License activation and device management

To use the Software, you must activate it on each Device by entering your License Key or clicking the activation link delivered to your email at purchase. Each activation records a Device identifier with our licensing server so that we can enforce the activation limits stated in Section 3.

If you reach your Tier's Device limit, you may deactivate an existing Device at any time through the customer portal at https://synaptix.bio/account/devices to free a slot for a new Device.

We do not collect, store, or transmit the contents of your DNA file or your analysis results during activation. Activation transmits only the License Key, a one-way hardware-derived Device identifier, and the Software version. See our Privacy Policy at https://synaptix.bio/legal/privacy-policy for full details.

6. No medical or clinical warranties

SynaptiX is provided for informational and educational purposes only. SynaptiX is not a substitute for professional medical advice, diagnosis, or treatment.

To be explicit:

(a) The Software is not a medical device. It has not been reviewed, approved, cleared, or certified by any regulatory authority for medical use.

(b) The Software's outputs — including polygenic risk score interpretations, trait reports, pharmacogenomic interpretations, and clinical screening result interpretations — are educational summaries of published scientific research. They are not diagnoses, prognoses, prescriptions, or recommendations for medical action.

(c) The polygenic risk scores reported by the Software are calibrated against the 1000 Genomes Project reference panel and validated against the PLINK 2.0 reference implementation. They are nonetheless statistical estimates with inherent uncertainty, and their accuracy is most established for users of European ancestry. We have made every reasonable effort to report this uncertainty honestly within the Software, but no PRS report should substitute for professional clinical judgment.

(d) The trait, pharmacogenomic, and screening data sourced from peer-reviewed scientific literature, CPIC guidelines, FDA drug labels, the PGS Catalog, ClinVar, and curated entries may be incomplete, may not reflect the latest research, and may not apply to your specific situation.

(e) Decisions about your health — including (without limitation) decisions about medications, screening tests, lifestyle changes, family planning, or any other matter affecting your well-being — should be made with the involvement of a qualified healthcare provider who has access to your full medical history.

You agree that you will not rely on SynaptiX as the sole basis for any health-related decision.

6.5 Specific feature disclaimers

The following disclaimers apply to specific SynaptiX features and supplement the general medical-use disclaimer in Section 6.

(a) Vaccine pharmacogenomics findings

SynaptiX may report pharmacogenomic findings related to vaccine response (for example, markers associated with hypersensitivity risk for specific vaccines). These findings are research-level pharmacogenomic summaries, not:

Immunization eligibility advice
Travel-medicine clearance
A contraindication determination (a decision that a vaccine must not be given to you)
A vaccine schedule or administration instruction

Vaccine scheduling, contraindications, and travel-medicine requirements depend on your full medical history, allergies, immunocompromise status, pregnancy, regional requirements, and live-vaccine interactions — none of which SynaptiX assesses. Discuss any vaccine-related finding with a qualified immunization or travel-medicine provider before acting on it, especially for live vaccines, G6PD-related considerations, immunocompromised status, pregnancy, known allergies, and regional immunization requirements.

(b) Medication input and brand-name resolution

SynaptiX lets you enter medication names by brand or generic form and resolves them on-device against a brand/synonym dictionary so the app can connect your input to the relevant pharmacogenomic findings. This brand-name resolution is a convenience recognition aid — it is not a confirmation that you are taking a particular formulation, dose, route of administration, indication, or combination product. Brand names can correspond to multiple formulations, and resolution may be ambiguous.

The flags shown on your MedicamentiX medication-safety card are pharmacogenomic research/guideline context for clinician review (e.g., CPIC Level A guideline findings expressed in source-attributed, referential framing). They are not start, stop, switch, or dose-adjustment instructions. Any item on your card should be verified by a clinician or pharmacist before any clinical action, and the card is intended to support — not replace — that conversation.

You may generate a QR code on your MedicamentiX card that encodes your medication and vaccine pharmacogenomic findings, card identity fields, and any emergency-contact name and phone number you entered into a link (a URL fragment) viewable at synaptix.bio/v/. The following terms apply:

You control whether to generate, print, or share the QR code or link. SynaptiX does not transmit the card contents on your behalf.
The health data is embedded in the URL fragment and is not sent to or stored on SynaptiX servers. When someone scans the QR or opens the link, their browser reads those contents locally from the URL.
To authenticate a newly generated card without reusing one trackable device key, the desktop app sends a one-card public key to the licensing service and receives a signed certificate containing a random card ID, that public key, and its issue time. The service stores the card ID, license/device authority, public key, lifecycle status, and timestamps. It does not receive the card contents.
When the viewer is online, it sends the random card ID to the SynaptiX status service and may show Current, Newer card exists, or Withdrawn. Replacing a card can mark the prior card as superseded, and deleting a public card can mark it withdrawn. The signed snapshot remains readable offline and status changes cannot erase a printed card, screenshot, saved link, or other copy already held by someone else.
Anyone who has the QR code or the link can view the encoded findings. The card has no reader authentication; it remains a bearer artifact, like a printed credit card or paper prescription. Online lifecycle status is context, not access control.
SynaptiX is not responsible for the security of physical cards or shared links after you generate them. You are responsible for controlling access to any printed card or shared link, the same way you would control any document containing your health information.

(d) Ancestry tab

The Ancestry tab provides educational heritage visualization based on your haplogroup calls and a principal-component ancestry projection. It is not:

Proof of identity
Proof of ethnicity, race, tribal affiliation, nationality, or citizenship
Proof of paternity, kinship, adoption, or genealogical relationship

Haplogroup calls and ancestry projections are probabilistic and coverage-limited: their resolution depends on which positions your DNA chip covers and on the reference data available for your lineage, and consumer-chip coverage often limits results to broad major-branch assignments. Do not rely on Ancestry tab output for any identity, legal, or genealogical purpose.

The interactive map in the Ancestry tab is rendered using map tiles served by CARTO/OpenStreetMap third-party infrastructure. When you view the map, your device requests tile images from CARTO servers, which may receive your IP address and request metadata. No SynaptiX data or genetic information is sent to CARTO or OpenStreetMap.

(e) Evidence tier badges

Some findings in SynaptiX carry an evidence-tier badge summarizing the source class of the evidence behind the finding:

CG — clinical guideline source (e.g., CPIC Level A guideline). Indicates the finding is drawn from a curated clinical-guideline source. It is not clinical validation that the finding applies to your specific case or that any clinical action is indicated for you.
PR — published research source. Indicates the finding is drawn from peer-reviewed research literature. Published-research findings are typically lower-certainty than guideline findings and do not constitute guideline-backed clinical action.

Evidence-tier badges summarize where the evidence comes from, not whether it is clinically validated for your situation. A CG or PR badge does not transform a finding into a diagnosis, prescription, or treatment recommendation.

(f) Biological sex as a required clinical input

SynaptiX uses biological sex (male/female) as a required clinical input for pharmacogenomic interpretation. Drug metabolism, dosing thresholds, reproductive safety warnings, and hormonal pathway analysis are sex-dependent in published clinical pharmacology literature. This selection directly affects the accuracy and safety of your medication report. It is not a statement of gender identity. Omitting or misrepresenting this input may result in clinically inaccurate output. Refunds will not be issued on the basis of the available biological sex options.

7. Disclaimer of warranties

To the maximum extent permitted by applicable law, the Software is provided "AS IS" and "AS AVAILABLE," without warranty of any kind, either express or implied.

The Operator expressly disclaims all warranties, including (without limitation):

Warranties of merchantability or fitness for a particular purpose
Warranties of accuracy, completeness, or currency of any information provided by the Software
Warranties that the Software will be uninterrupted, error-free, or free of harmful components
Warranties of non-infringement of any third party's intellectual property

Some jurisdictions do not permit the disclaimer of certain warranties. In such jurisdictions, the disclaimer above applies to the maximum extent permitted by law.

Nothing in this Section 7 limits, excludes, or waives any right, remedy, warranty, or condition that cannot be limited, excluded, or waived under applicable law, including (without limitation) the implied conditions and warranties of the Ontario Sale of Goods Act and any deemed conditions or warranties under the Ontario Consumer Protection Act, 2002.

8. Limitation of liability

To the maximum extent permitted by applicable law, the Operator's total cumulative liability to you for all claims arising from or related to the Software or this Agreement is limited to the amount you paid for your License (i.e., the purchase price of the License Key).

To be explicit about what this means:

(a) The Operator is not liable for any indirect, incidental, special, consequential, exemplary, or punitive damages arising from your use of the Software, including (without limitation) lost profits, lost revenue, lost data, business interruption, or any health-related outcome.

(b) The Operator is not liable for any decision you make in reliance on the Software's outputs, including any medical, treatment, screening, lifestyle, or family-planning decision.

(c) The Operator is not liable for the actions or omissions of any third party, including (without limitation) Stripe (the payment processor), Fireworks AI (the optional AI inference provider), your email service provider, your operating system vendor, or any source of the scientific data the Software relies upon.

This limitation of liability applies whether the claim is based on contract, tort (including negligence), strict liability, or any other legal theory, and whether or not the Operator has been advised of the possibility of such damages.

Some jurisdictions do not permit the limitation or exclusion of certain damages. In such jurisdictions, the limitation above applies to the maximum extent permitted by law.

Nothing in this Section 8 limits, excludes, or waives any liability that cannot be limited, excluded, or waived under applicable law, including (without limitation) liability for death or personal injury caused by negligence where applicable law prohibits exclusion of such liability, and any non-waivable rights, remedies, or causes of action you may have under applicable consumer protection legislation.

9. Refunds and future add-on status

9.1 Refunds for one-time license purchases

Refunds for one-time license purchases (the Individual tier and the Family tier) are issued only if SynaptiX cannot be installed and run on your computer's operating system or hardware configuration when that configuration meets the published minimum system requirements at https://synaptix.bio. Specifically:

If your system meets the published minimum requirements but the Software fails to install or run, you are entitled to a full refund. Contact hi@synaptix.bio within 30 days of purchase with a description of the failure.
If your system does not meet the published minimum requirements, the Software is not guaranteed to function, and refunds are at the Operator's discretion.
Refunds are not issued for buyer's remorse, change of mind, or dissatisfaction with the Software's findings.
Refunds are not issued on the basis of the available biological sex options (male/female) required for pharmacogenomic interpretation, as described in Section 6.5(f).

The Operator reserves the right to investigate refund requests, including by asking you for technical details about your system and the failure mode, before issuing a refund.

9.2 SynaptiX+ is not currently offered

SynaptiX+ is a reversible, default-off future add-on design. It is not currently sold, does not create a recurring payment obligation, and does not currently add profiles or unlock features. The former name "Dr. Prime+" is deprecated and must not be understood as a separate current product.

If the Operator later launches SynaptiX+, the checkout must show its price, billing period, cancellation method, profile-capacity effect, included features, and then-current legal terms before any customer subscribes. No language in this Agreement authorizes recurring billing for a product that has not launched.

9.3 Non-waivable consumer rights

This refund policy and future-product notice do not limit any cancellation, refund, warranty, or other rights you may have under applicable consumer protection legislation, including (without limitation) the Ontario Consumer Protection Act, 2002 and Ontario Regulation 17/05 (governing internet agreements).

10. Indemnification

You agree to indemnify, defend, and hold harmless the Operator and his successors and assigns from and against third-party claims, liabilities, damages, losses, and expenses (including reasonable legal fees) arising from or related to:

(a) Your use of the Software in material violation of this Agreement or in violation of applicable law. (b) Your analysis of any other person's DNA data without the consent and, where applicable, minor assent required by Section 4(f). (c) Your violation of any third party's rights (including, without limitation, privacy rights, genetic privacy laws, or intellectual property rights).

For clarity, this indemnification covers claims brought by parties other than you (e.g., a family member whose DNA you analyzed without consent and who later sues the Operator). It does not require you to indemnify the Operator against your own direct claims, which are addressed by Sections 7 and 8 (warranty disclaimer and limitation of liability) and Section 12 (dispute resolution).

11. Term and termination

This Agreement remains in effect for as long as you use the Software, subject to termination as follows:

(a) By you: You may terminate this Agreement at any time by uninstalling the Software from all Devices and ceasing all use of it.

(b) By the Operator: The Operator may terminate this Agreement, and revoke your License, if you materially breach this Agreement (including, without limitation, violating the restrictions in Section 4 or attempting to circumvent the activation system in Section 5). Where reasonably practicable, the Operator will provide notice of the breach and an opportunity to cure before terminating.

(c) Upon termination: All rights granted to you under this Agreement immediately cease. You must uninstall the Software from all Devices. Sections that by their nature survive termination (including Sections 6, 7, 8, 10, 12, and 13) survive termination.

12. Governing law and dispute resolution

12.1 Governing law

This Agreement is governed by the laws of the Province of Ontario, Canada, without regard to its conflict-of-laws principles. The United Nations Convention on Contracts for the International Sale of Goods does not apply.

12.2 Consumer rights preserved

For consumers, nothing in this Agreement prevents you from exercising any non-waivable rights under applicable consumer protection legislation, including (without limitation) the Ontario Consumer Protection Act, 2002. This includes the right to bring a claim in the Superior Court of Justice of Ontario or to participate in a class proceeding where such rights cannot be waived by contract.

12.3 Optional post-dispute resolution

After a dispute has arisen, the parties may mutually agree, in writing, to resolve the dispute by binding arbitration, mediation, or another lawful dispute-resolution procedure. Neither party is required to accept such a procedure, and no provision of this Agreement compels you to do so before a dispute arises.

12.4 Non-consumer / business disputes

If you are not a consumer within the meaning of applicable consumer protection legislation (for example, if you are using SynaptiX in connection with a business, profession, or commercial activity), disputes between you and the Operator shall be resolved by binding individual arbitration in Toronto, Ontario, Canada, administered under the Ontario Arbitration Act, 1991, unless prohibited by applicable law. Such arbitration shall be conducted in English by a single arbitrator.

12.5 Carve-outs

Nothing in this Section 12 limits either party's right to seek injunctive or equitable relief in a court of competent jurisdiction for the protection of intellectual property rights or to enforce confidentiality obligations, where the law permits such relief.

13. Entire agreement; severability; assignment; updates

(a) Entire agreement. This Agreement, together with the SynaptiX Privacy Policy and Terms of Service, constitutes the entire agreement between you and the Operator regarding the Software, and supersedes all prior or contemporaneous agreements, communications, and proposals on the subject.

(b) Severability. If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions remain in full force and effect.

(c) No waiver. The Operator's failure to enforce any provision of this Agreement does not constitute a waiver of that provision or any other provision.

(d) Assignment. You may not assign this Agreement or any of your rights under it. The Operator may assign this Agreement to a successor entity, including upon incorporation of SynaptiX as a legal entity (e.g., SynaptiX LLC in the State of Arkansas, United States). In the event of such assignment, the Operator will notify you and update the operating-entity references in this Agreement.

(e) Updates. The Operator may update this Agreement from time to time. Material updates will be communicated by email to the address associated with your License. Continued use of the Software after the effective date of an update constitutes your acceptance of the updated Agreement. If you do not accept an update, your sole remedy is to discontinue use of the Software.

14. Contact

Questions about this Agreement, license activation issues, refund requests, or other matters:

Email: hi@synaptix.bio Operator: Paris Valentino Iason Kollias Location: Ontario, Canada

By installing or activating SynaptiX, you confirm that you have read, understood, and agreed to be bound by this End User License Agreement.